TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21870913

Group type: EXPERIMENTAL
Intervention: Perceptual learning through challenging visual tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training protocols targeting stereo acuity deficits
Number of subjects: 0
Study: 19674806

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/day (n=19)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: metformin 850 mg/day (n=16)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MNT alone (n=15)
Number of subjects: 50
Study: 17405972

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739

Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 10739
Study: 15283218

Group type: EXPERIMENTAL
Intervention: Intracameral preservative-free 1% xylocaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 11217909

Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype DD
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype II and DD
Number of subjects: 20
Study: 9763048

Group type: EXPERIMENTAL
Intervention: Partogram with a 4-hour action line
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Partogram with a 2-hour action line
Number of subjects: 928

Group type: COMPARATOR
Intervention: Partogram with a 3-hour action line
Number of subjects: 928
Study: 7871964

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 20
Study: 3277400

Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal anti-T cell antibody
Number of subjects: 34

Group type: COMPARATOR
Intervention: Triple immunosuppression (cyclosporine, azathioprine, prednisone)
Number of subjects: 34
Study: 29665351

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27296086

Group type: EXPERIMENTAL
Intervention: Healthy Weight (HW) intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (HPV vaccination awareness intervention)
Number of subjects: 58
Study: 26713528

Group type: EXPERIMENTAL
Intervention: High-dose UTI (16000 U/kg i.v.)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Low-dose UTI (8000 U/kg i.v.)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: High-dose UTI and Low-dose UTI
Number of subjects: 127
Study: 23715170

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg per day
Number of subjects: 287
Study: 21044330

Group type: EXPERIMENTAL
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 41
Study: 18427971

Group type: COMPARATOR
Intervention: Inactive comparison condition from a randomized HIV prevention trial (Project SHIELD)
Number of subjects: 0
Study: 16328283

Group type: EXPERIMENTAL
Intervention: VL thalamotomy
Number of subjects: 10
Study: 12478076

Group type: EXPERIMENTAL
Intervention: Rapid HIV-1 testing
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Conventional HIV-1 testing (ELISA)
Number of subjects: 1249
Study: 11708572

Group type: EXPERIMENTAL
Intervention: lysine clonixinate 125 mg plus propinox 10 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: paracetamol 500 mg plus hyoscine N‐butylbromide 10 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125

Group type: COMPARATOR
Intervention: baseline
Number of subjects: 125
Study: 9190553

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 20 ppm
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (100% oxygen)
Number of subjects: 53
Study: 1405330

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 121
Study: 3874774

Group type: EXPERIMENTAL
Intervention: Phentolamine (25 micrograms kg‐1 min‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Urapidil (100 micrograms kg‐1 min‐1)
Number of subjects: 20
Study: 30689172

Group type: EXPERIMENTAL
Intervention: Virtual Reality training (VR group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (without VR training)
Number of subjects: 10
Study: 28650790

Group type: EXPERIMENTAL
Intervention: Demonstration on a Model by Tell and Touch method (DMTT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self trained on oral hygiene skills
Number of subjects: 60
Study: 26535595

Group type: EXPERIMENTAL
Intervention: DR-prednisone
Number of subjects: 207

Group type: COMPARATOR
Intervention: IR-prednisone
Number of subjects: 207
Study: 23932307

Group type: EXPERIMENTAL
Intervention: IUI at 34‐36 h after hCG injection (group I, n=106)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: IUI simultaneously with hCG administration (group II, n=98)
Number of subjects: 220
Study: 20736941

Group type: EXPERIMENTAL
Intervention: Zinc salt (ZnCl2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic low-dose zinc exposure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of ZnCl2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zinc salt and proton pump inhibitor (PPI)
Number of subjects: 12
Study: 19750306

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 15 mL of 0.125% ropivacaine (EA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE group) with 5 microg of sufentanil plus 2.5mg bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE group)
Number of subjects: 40
Study: 17406133

Group type: EXPERIMENTAL
Intervention: Adult male circumcision
Number of subjects: 1475
Study: 12848630

Group type: EXPERIMENTAL
Intervention: Twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg
Number of subjects: 296

Group type: COMPARATOR
Intervention: Once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg
Number of subjects: 296
Study: 10671705

Group type: EXPERIMENTAL
Intervention: Remedial intervention (four 45-minute sessions of participation in computer tasks without instruction in compensatory strategies)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compensatory intervention (four 45-minute sessions of instruction in the use of three internal compensatory strategies: verbalization, chunking, and pacing)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (remedial and compensatory)
Number of subjects: 30
Study: 8923366

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (oral prostanoid prostaglandin I2 analog)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Beraprost sodium and Placebo
Number of subjects: 125
Study: 1756692

Group type: EXPERIMENTAL
Intervention: Amidotrizoic acid (2.1 osmol/kg; mean dosage 166 +/- 68 or 2.2 +/- 1.1 ml/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iopamidol (0.8 osmol/kg; mean dosage 154 +/- 78 ml or 2.1 +/- 1.0 ml/kg)
Number of subjects: 30
Study: 7124768

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6200729

Group type: EXPERIMENTAL
Intervention: Propranolol (0.0125 to 0.15 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29458320

Group type: EXPERIMENTAL
Intervention: 150 mL/min
Number of subjects: 100

Group type: COMPARATOR
Intervention: 250 mL/min
Number of subjects: 100
Study: 27158033

Group type: EXPERIMENTAL
Intervention: Acrylic resin-based surgical guides (Sg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgery (Co)
Number of subjects: 40
Study: 25436797

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chemotherapy (Pemetrexed)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chemotherapy (Docetaxel)
Number of subjects: 343
Study: 22089480

Group type: EXPERIMENTAL
Intervention: Normal BMI athletes (n = 150)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Normal BMI controls (n = 96)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Correlation between BMI and body fat percentage for athletes
Number of subjects: 938

Group type: COMPARATOR
Intervention: Correlation between BMI and body fat percentage for controls
Number of subjects: 938
Study: 19696755

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (4 x 30 min/week at >=70% of peak oxygen consumption (VO2peak))
Number of subjects: 29
Study: 17327869

Group type: EXPERIMENTAL
Intervention: Boiled potatoes (energy-equivalent meal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: French fries (energy-equivalent meal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Boiled potatoes (carbohydrate-equivalent meal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: French fries (carbohydrate-equivalent meal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Boiled potatoes with oil (carbohydrate-equivalent meal)
Number of subjects: 27

Group type: COMPARATOR
Intervention: White wheat bread (reference meal)
Number of subjects: 27
Study: 15977092

Group type: EXPERIMENTAL
Intervention: Oral rofecoxib 50 mg 1 h before surgery plus intraarticular 0.5 % bupivacaine 20 ml postoperatively
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intraarticular 0.5 % bupivacaine 20 ml postoperatively
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline 20 ml intraarticularly after surgery
Number of subjects: 62
Study: 12681866

Group type: EXPERIMENTAL
Intervention: Continuous use of 20 microg ethinyl estradiol/100 microg levonorgestrel for 12 cycles (336 days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 28-day cycles (21 active pills and a pill-free week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Continuous use of 20 microg ethinyl estradiol/100 microg levonorgestrel
Number of subjects: 79
Study: 10640841

Group type: EXPERIMENTAL
Intervention: Eosin 2% solution
Number of subjects: 54

Group type: COMPARATOR
Intervention: Zinc oxide paste
Number of subjects: 54

Group type: COMPARATOR
Intervention: Corticosteroid cream (clobetasone butyrate 0.05%)
Number of subjects: 54
Study: 9038393

Group type: EXPERIMENTAL
Intervention: Histopathologic examination of endometrial hyperplasias
Number of subjects: 87
Study: 1542817

Group type: EXPERIMENTAL
Intervention: Quadriceps endurance programme (experimental group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 6601201

Group type: EXPERIMENTAL
Intervention: Intensive medical management
Number of subjects: 70

Group type: COMPARATOR
Intervention: Urgent coronary bypass surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 70
Study: 30315239

Group type: EXPERIMENTAL
Intervention: ibrutinib (420 mg daily) + bendamustine and rituximab (BR)
Number of subjects: 578

Group type: COMPARATOR
Intervention: placebo + bendamustine and rituximab (BR)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: ibrutinib + BR
Number of subjects: 578

Group type: COMPARATOR
Intervention: placebo + BR
Number of subjects: 578
Study: 28988209

Group type: EXPERIMENTAL
Intervention: Forced air warming (FAW)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 140
Study: 26073718

Group type: EXPERIMENTAL
Intervention: Computer-based educational program (CHOICES)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care reformatted into a computer-based (e-Book) program
Number of subjects: 68
Study: 24854049

Group type: EXPERIMENTAL
Intervention: Inpatient weight loss intervention with postdischarge follow-up (weight education video, personalized counseling, specific goals)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Inpatient weight loss intervention with postdischarge follow-up
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 22401952

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 284

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 284
Study: 19565176

Group type: EXPERIMENTAL
Intervention: Screening for osteoporosis
Number of subjects: 4800

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 4800
Study: 18611422

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study: 16202724

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Laparotomic approach
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (matched women)
Number of subjects: 84
Study: 10921154

Group type: EXPERIMENTAL
Intervention: Huweigao externally applied at Shenque (Ren 8)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Weinaian capsule (oral administration)
Number of subjects: 140
Study: 8520750

Group type: EXPERIMENTAL
Intervention: 0.5% nedocromil sodium
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 1664792

Group type: EXPERIMENTAL
Intervention: Diets containing different amounts of protein and phosphorus with two levels of blood pressure control.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood pressure control levels.
Number of subjects: 0
Study: 7038656

Group type: EXPERIMENTAL
Intervention: Once-daily metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily metoprolol
Number of subjects: 0
Study: 27837321

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Internal Fixation (IF)
Number of subjects: 78
Study: 24903408

Group type: EXPERIMENTAL
Intervention: Less sweet beverages available at home
Number of subjects: 2047

Group type: EXPERIMENTAL
Intervention: Parents discouraged sweet beverage consumption
Number of subjects: 2047
Study: 23952184

Group type: EXPERIMENTAL
Intervention: Children with ADHD and one comorbid condition (ODD or ADs)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Children with ADHD and two comorbid conditions (ODD and ADs)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Children with ADHD alone
Number of subjects: 223
Study: 20716629

Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the second quartile (14%-19%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the third quartile (20%-29%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Post-treatment Ki-67 in the top quartile (≥30%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Baseline Ki-67
Number of subjects: 120
Study: 19761888

Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in obese group with Apo E3 genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E2 genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E3 genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 12-week worksite health promotion program in individuals with Apo E4 genotype
Number of subjects: 141
Study: 16938752

Group type: EXPERIMENTAL
Intervention: Aerosolized rhDNase (Pulmozyme) 2(1/2) mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: No rhDNase treatment (control group)
Number of subjects: 0
Study: 15361814

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overt hypothyroidism (OH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Euthyroid controls
Number of subjects: 44
Study: 11028260

Group type: EXPERIMENTAL
Intervention: Atracurium (A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cisatracurium (C)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rocuronium (R)
Number of subjects: 151
Study: 9550765

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 2151
Study: 8382419

Group type: EXPERIMENTAL
Intervention: Live oral candidate rotavirus vaccines (RIT 4237, RRV‐1, DxRRV, DS1xRRV)
Number of subjects: 0
Study: 3764377

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study: 30353020

Group type: EXPERIMENTAL
Intervention: ADDWoR group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: OVX+ ADDWoR group
Number of subjects: 32

Group type: COMPARATOR
Intervention: OVX group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 27297006

Group type: EXPERIMENTAL
Intervention: Newhints intervention with CBSV assessments and referrals
Number of subjects: 16168

Group type: COMPARATOR
Intervention: Control group (no Newhints intervention)
Number of subjects: 16168
Study: 25533656

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops, administered once a day to both eyes.
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo eye drops, administered once a day to both eyes.
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 516
Study: 23910248

Group type: EXPERIMENTAL
Intervention: Telephone outreach intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cancer helpline calls
Number of subjects: 50
Study: 21788846

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 28
Study: 19431219

Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation (n = 26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (n = 25)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TBE parameter (height of barium column at 1 min)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TBE parameter (height at 1 min) post-treatment
Number of subjects: 51
Study: 16702582

Group type: EXPERIMENTAL
Intervention: Twice-a-week weight training for 6 months
Number of subjects: 45
Study: 15526714

Group type: EXPERIMENTAL
Intervention: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salt-losing CAH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sisters of CAH participants and women with polycystic ovary syndrome)
Number of subjects: 0
Study: 11391583

Group type: EXPERIMENTAL
Intervention: Paclitaxel 40 mg/m2 and estramustine 600 mg/m2 (Cohort I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 60 mg/m2 and estramustine 900 mg/m2 (Cohort II)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 75 mg/m2 and estramustine 900 mg/m2 (Cohort III)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m2 and estramustine 900 mg/m2 (Cohort IV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall response in Cohorts I-IV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall response in Cohorts II-IV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall response with measurable disease
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall PSA response
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Median duration of PSA response
Number of subjects: 18
Study: 9493121

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4-16 mg once a day
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil in combination with amlodipine or hydrochlorothiazide
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 5000
Study: 7648152

Group type: EXPERIMENTAL
Intervention: Complete local clearance as assessed by surgeon and pathologist
Number of subjects: 396

Group type: COMPARATOR
Intervention: Incomplete local clearance as assessed by surgeon and pathologist
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Complete local clearance in patients without metastatic disease
Number of subjects: 396

Group type: COMPARATOR
Intervention: Incomplete local clearance in patients without metastatic disease
Number of subjects: 396

Group type: COMPARATOR
Intervention: Disagreement in assessment of local clearance
Number of subjects: 396
Study: 2669713

Group type: EXPERIMENTAL
Intervention: Papaverine (60 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine (6 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline (10 ml)
Number of subjects: 34
Study: 1001084

Group type: EXPERIMENTAL
Intervention: Ammonium hydroxide odor source presented near the nose
Number of subjects: 20
Study: 31513839

Group type: EXPERIMENTAL
Intervention: 15 g E. angustifolia whole fruit powder
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (7.5 g cornstarch + 7.5 g isomalt)
Number of subjects: 58
Study: 30337695

Group type: EXPERIMENTAL
Intervention: Dorsal phalloplasty (DP) with penile prosthesis implantation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Penile prosthesis alone (Control)
Number of subjects: 126
Study: 28579538

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sham endoscopic procedure
Number of subjects: 127
Study: 25939657

Group type: EXPERIMENTAL
Intervention: Daily 81 mg aspirin for 14 days before exercise and a single dose of 325 mg aspirin immediately after exertion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin before exertion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Single-dose aspirin after exertion
Number of subjects: 52
Study: 24719046

Group type: EXPERIMENTAL
Intervention: Exercise group (3 exercise sessions per week for 3 months at 70% VO2MAX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study: 23285043

Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure variability (measured as standard deviation)
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Variability in diastolic blood pressure
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Pulse pressure variability
Number of subjects: 5804